Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Endocrine ophthalmopathy, Optic neuropathy
Clinical narrative: de novo active Thyroid Eye Disease; Progressed to dysthyroid optic neuropathy; This literature-non-study case was reported in a literature article and describes the occurrence of ENDOCRINE OPHTHALMOPATHY (de novo active Thyroid Eye Disease) and OPTIC NEUROPATHY (Progressed to dysthyroid optic neuropathy) in a 71-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.        The patient's past medical history included Non-smoker. Concurrent medical conditions included Hashimoto's disease (40-year history of hypothyroidism).    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) .5 milligram. On an unknown date, the patient experienced ENDOCRINE OPHTHALMOPATHY (de novo active Thyroid Eye Disease) (seriousness criterion medically significant) and OPTIC NEUROPATHY (Progressed to dysthyroid optic neuropathy) (seriousness criterion medically significant). At the time of the report, ENDOCRINE OPHTHALMOPATHY (de novo active Thyroid Eye Disease) and OPTIC NEUROPATHY (Progressed to dysthyroid optic neuropathy) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   It was reported that our case represent one of de novo active TED progressing to dysthyroid optic neuropathy.  Author concluded that new diagnosis or deterioration of thyroid eye disease (TED) after mRNA SARSCoV- 2 vaccination can occur, with most cases described in patients with underlying autoimmune thyroid disease. Our report raises awareness to this potential complication to promote early recognition and prompt management of TED associated with mRNA SARS-CoV-2 vaccines. Further studies are needed to explore the mechanism of TED following mRNA SARS-CoV-2 vaccination, risk factors, prevention and treatment.  Concomitant and treatment medication was not reported.  Company comment: This literature non study case concerns a 71-year-old, female patient with medical history of Hashimoto's disease (40-year history of hypothyroidism) , who experienced the unexpected serious (medically significant) events of endocrine ophthalmopathy and optic neuropathy. The events occurred on an unknown date after the second dose of mRNA-1273. As reported, case presents de novo active Thyroid Eye Disease progressing to dysthyroid optic neuropathy. No further information about the events was available at the time of the report for this specific patient. Author concluded that new diagnosis or deterioration of thyroid eye disease (TED) after mRNA SARS CoV- 2 vaccination can occur, with most cases described in patients with underlying autoimmune thyroid disease. Medical history of Hashimoto's thyroiditis is a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This literature non study case concerns a 71-year-old, female patient with medical history of Hashimoto's disease (40-year history of hypothyroidism) , who experienced the unexpected serious (medically significant) events of endocrine ophthalmopathy and optic neuropathy. The events occurred on an unknown date after the second dose of mRNA-1273. As reported, case presents de novo active Thyroid Eye Disease progressing to dysthyroid optic neuropathy. No further information about the events was available at the time of the report for this specific patient. Author concluded that new diagnosis or deterioration of thyroid eye disease (TED) after mRNA SARS CoV- 2 vaccination can occur, with most cases described in patients with underlying autoimmune thyroid disease. Medical history of Hashimoto's thyroiditis is a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.